Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
University Basel, Basel, Switzerland. klazien.matter@unibas.ch.|Swiss Group of Clinical Cancer Research (SAKK) Coordinating Centre, Bern, Switzerland. klazien.matter@unibas.ch.
K
http://orcid.org/0000-0002-5143-8112
K
Matter-Walstra
University Basel, Basel, Switzerland.
M
M
Schwenkglenks
Swiss Group of Clinical Cancer Research (SAKK) Coordinating Centre, Bern, Switzerland.|University Hospital Zürich, 8091, Zurich, Switzerland.
K J
KJ
Dedes
D001943:Breast Neoplasms; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D000077289:Letrozole; D009570:Nitriles; D010879:Piperazines; D011725:Pyridines; D011960:Receptors, Estrogen; D014230:Triazoles
D009570:Nitriles; D010879:Piperazines; D011725:Pyridines; D011960:Receptors, Estrogen; D014230:Triazoles; D000077289:Letrozole; C500026:palbociclib